398 related articles for article (PubMed ID: 12557435)
1. [Usefulness of CEA, CA 15-3 and CA 125 tumor markers in the differential diagnostics of peritoneal effusion].
Kiluk MS; Rółkowski R; Zawadzki RJ; Wojtukiewicz MZ
Pol Merkur Lekarski; 2002 Oct; 13(76):298-301. PubMed ID: 12557435
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of CA 72-4, carcinoembryonic antigen, CA 15-3, and CA 19-9 assay in pleural fluid. A study of 207 patients.
Villena V; López-Encuentra A; Echave-Sustaeta J; Martín-Escribano P; Ortuño-de-Solo B; Estenoz-Alfaro J
Cancer; 1996 Aug; 78(4):736-40. PubMed ID: 8756365
[TBL] [Abstract][Full Text] [Related]
3. The importance of serum and ascites fluid alpha-fetoprotein, carcinoembryonic antigen, CA 19-9, and CA 15-3 levels in differential diagnosis of ascites etiology.
Sari R; Yildirim B; Sevinc A; Bahceci F; Hilmioglu F
Hepatogastroenterology; 2001; 48(42):1616-21. PubMed ID: 11813585
[TBL] [Abstract][Full Text] [Related]
4. The diagnostic usefulness of tumour markers CEA and CA-125 in pleural effusion.
Sthaneshwar P; Yap SF; Jayaram G
Malays J Pathol; 2002 Jun; 24(1):53-8. PubMed ID: 16329556
[TBL] [Abstract][Full Text] [Related]
5. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer.
Molina R; Filella X; Zanon G; Pahisa J; Alicarte J; Munoz M; Farrus B; Ballesta AM
Anticancer Res; 2003; 23(2A):1043-50. PubMed ID: 12820345
[TBL] [Abstract][Full Text] [Related]
6. Detection of tumor markers including carcinoembryonic antigen, APC, and cyclin D2 in fine-needle aspiration fluid of breast.
Lee A; Kim Y; Han K; Kang CS; Jeon HM; Shim SI
Arch Pathol Lab Med; 2004 Nov; 128(11):1251-6. PubMed ID: 15508191
[TBL] [Abstract][Full Text] [Related]
7. Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer.
Eskelinen M; Kataja V; Hämäläinen E; Kosma VM; Penttilä I; Alhava E
Anticancer Res; 1997; 17(2B):1231-4. PubMed ID: 9137478
[TBL] [Abstract][Full Text] [Related]
8. Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer.
Findeisen R; Albrecht S; Richter B; Deutschmann K; Zimmermann T; Distler W
Luminescence; 2000; 15(5):283-9. PubMed ID: 11038485
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of tumor markers in peritoneal lavage in advanced gastric cancer.
Yamamoto M; Baba H; Kakeji Y; Endo K; Ikeda Y; Toh Y; Kohnoe S; Okamura T; Maehara Y
Oncology; 2004; 67(1):19-26. PubMed ID: 15459491
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15-3.
Lumachi F; Brandes AA; Boccagni P; Polistina F; Favia G; D'Amico DF
Anticancer Res; 1999; 19(5C):4485-9. PubMed ID: 10650797
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of CEA and CA 15-3 in the follow up of invasive breast cancer.
Sütterlin M; Bussen S; Trott S; Caffier H
Anticancer Res; 1999; 19(4A):2567-70. PubMed ID: 10470196
[TBL] [Abstract][Full Text] [Related]
12. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study.
Guadagni F; Ferroni P; Carlini S; Mariotti S; Spila A; Aloe S; D'Alessandro R; Carone MD; Cicchetti A; Ricciotti A; Venturo I; Perri P; Di Filippo F; Cognetti F; Botti C; Roselli M
Clin Cancer Res; 2001 Aug; 7(8):2357-62. PubMed ID: 11489813
[TBL] [Abstract][Full Text] [Related]
13. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
Ayhan A; Guven S; Guven ES; Kucukali T
Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
[TBL] [Abstract][Full Text] [Related]
14. [Standards, Options and Recommendations (SOR) for tumor markers in breast cancer. SOR Working Group].
Basuyau JP; Blanc-Vincent MP; Bidart JM; Daver A; Deneux L; Eche N; Gory-Delabaere G; Pichon MF; Riedinger JM
Bull Cancer; 2000 Oct; 87(10):723-37. PubMed ID: 11084536
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer.
Molina R; Filella X; Alicarte J; Zanon G; Pahisa J; Munoz M; Farrus B; Ballesta AM
Anticancer Res; 2003; 23(2A):1035-41. PubMed ID: 12820344
[TBL] [Abstract][Full Text] [Related]
16. Clinical value of TPS, CEA and CA 15-3 in breast cancer patients.
Blijlevens NM; Oosterhuis WP; Oosten HR; Mulder NH
Anticancer Res; 1995; 15(6B):2711-6. PubMed ID: 8669851
[TBL] [Abstract][Full Text] [Related]
17. N(1),N(12)-Diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers.
Hiramatsu K; Takahashi K; Yamaguchi T; Matsumoto H; Miyamoto H; Tanaka S; Tanaka C; Tamamori Y; Imajo M; Kawaguchi M; Toi M; Mori T; Kawakita M
Clin Cancer Res; 2005 Apr; 11(8):2986-90. PubMed ID: 15837752
[TBL] [Abstract][Full Text] [Related]
18. Combination of cancer antigen 125 and carcinoembryonic antigen can improve ovarian cancer diagnosis.
Sørensen SS; Mosgaard BJ
Dan Med Bull; 2011 Nov; 58(11):A4331. PubMed ID: 22047929
[TBL] [Abstract][Full Text] [Related]
19. The effect of maternal age, parity, and fetal sex on the amniotic fluid and maternal serum levels of CA 125, CA 19.9, CA 15.3, and CEA.
Tayyar M; Tutus A
Int J Fertil Womens Med; 1999; 44(5):256-9. PubMed ID: 10569455
[TBL] [Abstract][Full Text] [Related]
20. [Comparative evaluation of diagnostic significance of carbohydrate antigen CA125 and cancer-embryonal antigen in ovarian cancer].
Lapchenkov VI; Dudarev AL; Vinokurov VL; Iurkova LE; Barbanel EIu
Vestn Rentgenol Radiol; 1993; (5):30-1. PubMed ID: 7801580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
